Here are the 10-K annual reports from Innoviva, Inc. (INVA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INVA filings page.
Innoviva, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025. The amendment is made to comply with Rule 3-09 of Regulation S-X and updates the exhibits section to add separate financial information for an equity investee.
The filing includes the Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. as of December 31, 2025 and 2024 and for the years then ended, along with the related consent from Armata’s independent registered public accounting firm, Ernst & Young LLP. It also provides new certifications from Innoviva’s principal executive and principal financial officers.
The amendment states that, apart from these added exhibits and certifications, all disclosures remain unchanged from the original Annual Report. As of June 30, 2025, the aggregate market value of Innoviva’s common equity held by non‑affiliates was $1.26 billion, and on February 13, 2026, 74,073,646 shares of common stock were outstanding.
Innoviva, Inc. filed its annual report outlining its evolution from a pure royalty business into a diversified biopharmaceutical company. It earns royalties from GSK’s respiratory drugs RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, with tiered rates up to 15% of global net sales.
The company now runs a hospital-focused critical care and infectious disease platform anchored by five FDA-approved products: GIAPREZA®, XACDURO®, XERAVA®, ZEVTERA® and NUZOLVENCE®. These treat severe conditions such as septic shock, carbapenem-resistant Acinetobacter infections, complicated intra-abdominal infections, serious bacterial pneumonias and uncomplicated gonorrhea.
Innoviva highlights regulatory exclusivity, including QIDP designations and extended market protection periods, and notes active competition from numerous branded and generic antibiotics. It also emphasizes disciplined capital deployment, strategic stakes in other healthcare companies and a strategy focused on high unmet medical needs.